Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.
Nationwide Children's Hospital
Summary
A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
Description
This investigation is a prospective, open-labeled clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC. Patients will be monitored for adverse events (AE) and serious adverse events (SAE). Special attention will be paid to the incidence of stenosis. We will determine graft-related morbidity and mortality for the second generation TEVGs which will include any post-operative complication such as any aneurismal dilation, stenosis, thromboembolic or infectious event that requires treatment and is thought to be caused by the graft as determin…
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients will be eligible for inclusion in the study if they meet all of the following criteria. 1. Patient must be a candidate to undergo an extracardiac total cavopulmonary connection. 2. Patient and/or legal guardian must voluntarily provide informed consent/assent for participation in the study. Exclusion Criteria: * Patients will be excluded from participation in the study if they meet any of the following criteria. 1. Patient has an urgent/emergent operative status. 2. Patient has acute renal failure or renal insufficiency in the opinion of the investig…
Interventions
- Combination ProductTissue Engineered Vascular Grafts
Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
Location
- Nationwide Children's HospitalColumbus, Ohio